CA15-3 Cancer Antigen

Added to your cart

CA15-3 Cancer Antigen

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P301-4

£193.49

Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

CA15-3 is a normal product of breast cells, however in cancer it is frequently over-expressed. The CA15-3 marker is most widely used for monitoring the response to therapy of breast cancer patients. It is elevated in up to 70% of patients with metastatic disease, however, as it is only elevated in 3% of those with localised cancer there is no role for screening with this marker.

10ku
P301-4

More information

Attributes

Description

  • Shipping Information
  • Dry Ice
  • Abbreviations
  • CA15-3
  • Specification
  • > 10 Ku/ml CA15-3
  • Recommended Use
  • Research and further manufacturing
  • Preservatives
  • 0.09% NaN3
  • Buffer
  • 0.05M sodium phosphate buffer, pH 7.5 containing 0.15M NaCl
  • Presentation Matrix
  • 0.05M phosphate buffer, pH 7.5 containing 1M NaCl and 0.09% NaN3
  • Purity/grade
  • Low Cross Contamination, >10 Ku/mL
  • Source
  • Human Cell Line
  • Applications
  • Biosensors, Clinical Chemistry, Control Manufacture, ELISA, Lateral Flow, Life Science
  • Molecular weight
  • ~400kDa

Technical Documents

Certificates Of Analysis (105.29KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox